Skip to main content


The invention is a digital interface on the electronic device for identifying human or electronic activation of the device. The user is challenged with an image captcha consisting of various panels and is asked to identify the challenge points. The image-based captcha challenge is repeated at least twice in tandem to ensure user identity as a human. The electronic device is configured to detect at least one input from the user in both challenges and it allows access to the use of the electronic device only when both inputs match.



  • Secure access to the electronic device

  • Security check for use of various laboratory instruments

  • If the security device is linked with an alarm system, it can be used in sectors containing sensitive equipment/machines to warn of unauthorized access.



  • Secures authorized use of the electronic device




The invention is a cell line with selectively inducible knockdown of STIM1 in human Neural precursor cells (hNPCs), thereby leading to pre-mature differentiation into neuronal cells. The said hNPCs derived from human pluripotent stem cells have been stably transduced with inducible lentiviral constructs for the knockdown of STIM1 thereby changing the gene expression. Induced knockdown of STIM-1 decreases the proliferation of hNPCs and induces premature neurogenesis.




  • Research in neurodegenerative disorders where intracellular calcium signaling is considered causative including Alzheimer’s, Huntington’s, Parkinson’s, and Spinocerebellar ataxias.

  • Drug screening and toxicity testing assay.

  • This assay can be developed into commercial drug testing and toxicity testing for various neurodegenerative diseases through regulatory approvals



  • Customized induction of hNPCs from proliferative to differentiation into preferred neuronal cells.



Patented granted (Patent No. 399095)




Scientists at the National Centre for Biological Sciences have developed a microfluidic device that works on an adapted membrane deflection technique that enables periodic, partial, and complete immobilization of translucent organisms without affecting health conditions. The device is capable of tracking physiological changes in body size and locomotory behavior of translucent organisms such as Drosophila larvae, C. elegans, and zebrafish larvae throughout their lifespan.





The microfluidic device has a plurality of layers such as a flow channel layer having inlet reservoir(s) and outlet reservoir(s) to introduce a translucent organism, a microfluidic channel to allow the translucent organism to flow, a control channel layer comprising a main trap to immobilize the organism and a channel trap to retain the organism within the microfluidic channel. The flow channel layer and control channel layer are bonded together onto a glass coverslip to form a microfluidic device. Growth of the translucent organism can be monitored using low magnification bright field imaging and cellular phenomena in the organism can be monitored using high-resolution fluorescence imaging.



  • High-resolution imaging of subcellular processes in C. elegans and Drosophila can be readily adapted to other transparent or translucent organisms.

  • The device can be used in laser ablation, live transport imaging, behavioral analysis, calcium cell body imaging, cell division, and migration.



  • The device provides an advantage over other conventional immobilization methods as it allows longitudinal fluorescence imaging of the live organism without damaging or affecting its health under optimized conditions.

  • The technology described herein is capable of acquiring cellular and sub-cellular fluorescence images of translucent model organisms over a longer time scale.



Indian Patent pending - 640/CHE/2011




The invention discloses a process of preparing nanoparticles of a stable delivery complex comprising conformationally-restricted amino acid and a charged amino acid for delivering small molecule and nucleic acid molecules.

The existing drug delivery vehicle has limitations including poor bioavailability, instability in the circulation, inadequate tissue distribution, and potential toxicity during long-term administration. The current disclosure provides a highly stable dual delivery complex that simultaneously delivers two different cargo molecules to a target site without affecting the bioavailability. It is also a stable complex that does not undergo enzymatic degradation in vivo conditions.



  • Enables simultaneous delivery of two different therapeutic molecules to target two different pathways at the disease site.

  • Selectively deliver both anti-cancer and/or nucleic acid molecules to cancer cells.



  • Highly stable and easy to synthesize

  • Biocompatible and non-toxic

  • Economic and convenient process

  • The process provides better yields and purity of peptides

  • High entrapment efficiency

  • Controlled release of cargo molecules



The invention has been filed as a PCT application (PCT/IN2021/050170).




DNA damage is central to chemical carcinogenesis and occurs due to continuous exposure to various endogenous and exogenous genotoxic agents. Different carcinogens create a variety of metabolites, which can form significant modifications (adducts) in the DNA strands. Such DNA adducts have the potential to inhibit the DNA replication process. The presence of these adducts leads to the recruitment of pathways and molecules that serve to neutralize their deleterious effects on replication and remove them from the genome. Failure to neutralize the deleterious effects of the damaged nucleotide can lead to genetic instability, which generally leads to the death or oncogenic transformation of the cell.

DNA can be used as an agent that binds to ligands with high specificity. DNA modification helps improve its stability against nucleases, specificity to targets, and reduces immunostimulatory properties. Scientists at National Centre for Biological Sciences and the Indian Institute of Technology, Bombay have synthesized a compound named N2-furfuryl deoxyguanosine (dG) Phosphoramidite. This compound can be incorporated into oligonucleotides to obtain a modified DNA. DNA containing N2-furfuryl dG modification offers many potential therapeutic applications.



N2-furfuryl modified oligonucleotides may find application in regulation of gene expression, for studying structural and functional properties of Y-family polymerases, and for cross-linking of nucleic acids.



- A quick and improved process for preparing deoxyguanosine phosphoramidite by utilizing fewer amounts of reagents with simple purification steps.

- The process is advantageously scalable to satisfy the requirements of industrial production.

- The process eliminates the need for time-consuming and labor-intensive chromatographic purification steps and keeps undesired racemization at acceptable levels.



Indian patent IN295309 granted.




Rice is a primary source of nutrition worldwide. With the increase in population and changes in climate change, there is an increased demand for production and adaptable strains. Rice Domestication is a difficult and long-term process that may cause a loss of resistance to pests. The need to develop, better, high-yielding strains without losing the traits of disease resistance is high.

The inventors at the National Centre of Biological Sciences have developed a method of modulating the expression of the laccase gene by inhibiting its binding to miRNA. The inhibition involves transfecting the plant/calli with a short tandem mimic (STTM) which binds to the miRNA, inhibiting its binding to the laccase gene. Another aspect is mutating the laccase gene’s miRNA binding site to prevent the binding of miRNA to the gene.



  • Applicable over a wide range of semi-aquatic plants such as maize and tomato.

  • Could increase plant rigidity, aiding its growth in flood-prone regions.

  • The technology’s expansion to increase the yield of other non-semi aquatic crops can be contemplated.



The current inventive method of domesticating and producing transgenic plants produces crops with the following traits:

  • Increased laccase expression.

  • Increased crop yield per panicle.

  • Increased seed setting rate.

  • Increased leaf height.

  • Increased leaf width.

  • Increased plant height.



Patent Application No: IN201841039599




Neurodegenerative diseases arise from a progressive loss of structure and function of neurons leading to conditions including Parkinson’s, Alzheimer’s, Huntington’s, and multiple sclerosis. Most patients use L-DOPA for treatment which can lead to long-term motor complications. In addition, most of the currently available therapeutics can only reduce the symptoms and there is a need for a complete remedy.

The present invention relates to a method of managing neurodegenerative by administering an effective amount of a compound (tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof) capable of inhibiting or modulating inflammation in the subject. It mainly inhibits neuroinflammation in neurons surrounding cells.



  • Effective compound for managing the neuroinflammation-mediated neurodegenerative disease.

  • It can be used for Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple sclerosis, and amyotrophic lateral sclerosis.



  • The composition is formulated into dosage form selected from groups comprising a solid oral formulation, liquid formulation, and parenteral formulation or any combinations thereof.

  • Controlled as well as prolonged-release formulations are contemplated.


A PCT application has been filed bearing application number PCT/IB2017/053362.




The invention relates to a microfluidic analyzer for pathological detection. Currently, HIV diagnosis is carried out using ELISA or conventional flow cytometry which has disadvantages including the requirement of expensive chemicals, thorough maintenance, and experienced medical professionals to operate and maintain them effectively.



  • Quantitative HIV detection

  • Cell culture assays (counting non-fluorescent cell population)

  • Environment control (water contamination counter)

  • Blood count and oncological application (counting cell proliferation)

  • Detection of fluorescently labeled immune cells

  • Quantitation of infection level



  • Low cost

  • Portable device

  • The volume of sample required is low

  • Ease of maintenance

  • Ease of modification and upgradability



US: Patent granted (20140374630)

Europe: Patent pending (EP2810063)




The invention provides a method of introducing and over-expressing cockroach (Pacific Beetle) gene for milk protein in food-grade yeast (in-vitro host expression system) and obtaining powder or crystalline form of the high-calorific value recombinant protein which can be used as food or animal feed supplement. The protein supplement is made up of all essential amino acids, non-lactose sugars, and essential fatty acids. It provides about ~4X energy more than most mammalian milk.



  • High-calorie protein supplement in animal feed

  • Fortification blends into food and beverages

  • Serve as treatment, medicinal, curative, therapy, and/or prophylactic means for protein-energy malnourished (PEM) patients, at-risk populations, and/or as parenteral nutrition for imbecile patients

  • Longer boosters for distant cyclers, runners, and athletes.

  • Consumption as a direct supplement



  • High expression of the protein

  • Ease of culturing and maintenance

  • Low-cost production

  • Easy to pack and High shelf life

  • Time-release of nutrients



This invention has been filed with a provisional specification IN202141001050 in India.